Journal
VIRAL IMMUNOLOGY
Volume 32, Issue 9, Pages 370-382Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/vim.2019.0047
Keywords
PRRSV; chimeric protein; immunization
Categories
Funding
- Fondo Sectorial de Innovacion Secretaria de Economia-CONACYT (FINNOVA) [238667]
- Programa de Estimulos a la Innovacion (CONACYT-PEI) [244089]
Ask authors/readers for more resources
Porcine reproductive and respiratory syndrome virus (PRRSV) still poses a threat to the swine industry worldwide. Currently, commercial vaccines against PRRSV, which consist of modified live or inactivated virus, reduce symptoms and viremia in immunized pigs, but efficacy against heterologous strains is variable. This has led to the development of subunit vaccines that contain viral antigens that show the highest variability. In this work, a chimeric protein comprising short amino acid sequences from glycoprotein 3 (GP3), glycoprotein 4 (GP4), glycoprotein 5 (GP5), and M (matrix protein) proteins of PRRSV was designed and expressed in Escherichia coli. This protein, designated as PRRSVchim, was purified by immobilized metal affinity chromatography and evaluated. PRRSVchim was identified by immunoglobulin G (IgG) presence in serum samples from PRRSV-positive pigs. Also, the protein probed to be antigenic in immunized mice and piglets and provided some degree of protection against challenge with a PRRSV field isolate. These results show the potential of PRRSVchim protein for both PRRSV diagnostic and immunoprophylaxis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available